Strides returns to Australia via Aspen deal
This article was originally published in Scrip
Strides Arcolab is making a comeback in Australia. The Indian firm, which had divested its Australian business to Actavis (then Watson) in 2012, is acquiring a portfolio of around 130 products from Aspen Australia for approximately A$265m.
You may also be interested in...
Strides founder Arun Kumar says he’s succeeded in putting the company back on the road to health after it shocked financial markets by swinging to a quarterly loss last year. But as part of the recovery plan, the company is selling its key Australia generic business to “double-down” on the US market.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.